I'm now hearing Oppenheimer is out with an upgrade on Omrix Biopharma (NASDAQ:OMRI), taking their rating to Buy from Hold saying they believe investors are overreacting to a revenue shortfall of roughly $8mm in IVIG sales to one customer, and would use any pullback in the share price as a buying opportunity.
Firm's tgt is $35.
Notablecalls: Nice move by OpCo! See below for further deets. I continue to see OMRI as actionable here.
Firm's tgt is $35.
Notablecalls: Nice move by OpCo! See below for further deets. I continue to see OMRI as actionable here.
Thank you.. Took your advice.. Made an investment at open ... made about $3. /share before the trailing stop kicked in ( my mistake setting it too tight for the volatility)
ReplyDelete